by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.dexfenfluraminethioridazine will increase the level or effect of dexfenfluramine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.dextroamphetaminethioridazine will increase the level or effect of dextroamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.dextromethorphanthioridazine will increase the level or effect of dextromethorphan by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.donepezilthioridazine will increase the level or effect of donepezil by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.doxepindoxepin, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.doxepin, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.enalaprilthioridazine increases effects of enalapril by unspecified interaction mechanism. Minor/Significance Unknown.encainidethioridazine will increase the level or effect of encainide by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.ethanolethanol, thioridazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.eucalyptusthioridazine and eucalyptus both increase sedation. Minor/Significance Unknown.fesoterodinethioridazine will increase the level or effect of fesoterodine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.fluphenazinethioridazine will increase the level or effect of fluphenazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.fosinoprilthioridazine increases effects of fosinopril by unspecified interaction mechanism. Minor/Significance Unknown.galantaminethioridazine will increase the level or effect of galantamine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.glycopyrrolatethioridazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.glycopyrrolate inhaledthioridazine increases toxicity of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.imidaprilthioridazine increases effects of imidapril by unspecified interaction mechanism. Minor/Significance Unknown.imipramineimipramine, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.imipramine, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.lisinoprilthioridazine increases effects of lisinopril by unspecified interaction mechanism. Minor/Significance Unknown.lofepraminelofepramine, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.lofepramine, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.loratadinethioridazine will increase the level or effect of loratadine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.maprotilinemaprotiline, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.metyraponethioridazine decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.metyrosinemetyrosine increases toxicity of thioridazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased extrapyramidal symptoms.moexiprilthioridazine increases effects of moexipril by unspecified interaction mechanism. Minor/Significance Unknown.nortriptylinenortriptyline, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.nortriptyline, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.oxybutyninoxybutynin increases toxicity of thioridazine by unspecified interaction mechanism. Minor/Significance Unknown.oxybutynin topicaloxybutynin topical increases toxicity of thioridazine by unspecified interaction mechanism. Minor/Significance Unknown.oxybutynin transdermaloxybutynin transdermal increases toxicity of thioridazine by unspecified interaction mechanism. Minor/Significance Unknown.oxycodonethioridazine decreases effects of oxycodone by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of oxycodone to active metabolite morphine.pentobarbitalthioridazine decreases levels of pentobarbital by unspecified interaction mechanism. Minor/Significance Unknown.perhexilinethioridazine will increase the level or effect of perhexiline by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.perindoprilthioridazine increases effects of perindopril by unspecified interaction mechanism. Minor/Significance Unknown.perphenazinethioridazine will increase the level or effect of perphenazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.phenobarbitalthioridazine decreases levels of phenobarbital by unspecified interaction mechanism. Minor/Significance Unknown.primidonethioridazine decreases levels of primidone by unspecified interaction mechanism. Minor/Significance Unknown.prochlorperazinethioridazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.promazinethioridazine will increase the level or effect of promazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.promethazinethioridazine will increase the level or effect of promethazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.protriptylineprotriptyline, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.protriptyline, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.pyrimethaminepyrimethamine increases levels of thioridazine by decreasing metabolism. Minor/Significance Unknown.quinaprilthioridazine increases effects of quinapril by unspecified interaction mechanism. Minor/Significance Unknown.ramiprilthioridazine increases effects of ramipril by unspecified interaction mechanism. Minor/Significance Unknown.risperidonethioridazine will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.sagethioridazine and sage both increase sedation. Minor/Significance Unknown.secobarbitalthioridazine decreases levels of secobarbital by unspecified interaction mechanism. Minor/Significance Unknown.tolterodinethioridazine will increase the level or effect of tolterodine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.trandolaprilthioridazine increases effects of trandolapril by unspecified interaction mechanism. Minor/Significance Unknown.trazodonetrazodone, thioridazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trifluoperazinethioridazine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.trimipraminetrimipramine, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.tropisetronthioridazine will increase the level or effect of tropisetron by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.abirateroneMonitor Closely (1)abiraterone increases levels of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.abobotulinumtoxinAMonitor Closely (1)abobotulinumtoxinA increases effects of thioridazine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.aclidiniumMonitor Closely (2)aclidinium decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. thioridazine increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.acrivastineMonitor Closely (1)acrivastine and thioridazine both increase sedation. Use Caution/Monitor.adagrasibSerious - Use Alternative (2)adagrasib will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of adagrasib, a CYP2D6 inhibitor, with sensitive CYP2D6 substrates unless otherwise recommended in the prescribing information for these substrates. adagrasib, thioridazine. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.albiglutideMonitor Closely (1)thioridazine, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.albuterolContraindicated (1)albuterol and thioridazine both increase QTc interval. Contraindicated.Monitor Closely (1)thioridazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanilMonitor Closely (1)alfentanil and thioridazine both increase sedation. Use Caution/Monitor.alfuzosinContraindicated (1)alfuzosin and thioridazine both increase QTc interval. Contraindicated.Monitor Closely (1)thioridazine and alfuzosin both increase QTc interval. Use Caution/Monitor.alprazolamMonitor Closely (1)alprazolam and thioridazine both increase sedation. Use Caution/Monitor.amantadineMinor (1)amantadine increases toxicity of thioridazine by pharmacodynamic synergism. Minor/Significance Unknown. May increase Parkinsonian tremor.amifampridineMonitor Closely (1)thioridazine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.aminolevulinic acid oralSerious - Use Alternative (1)aminolevulinic acid oral, thioridazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.aminolevulinic acid topicalSerious - Use Alternative (1)thioridazine increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.amiodaroneContraindicated (1)thioridazine and amiodarone both increase QTc interval. Contraindicated.Serious - Use Alternative (2)amiodarone increases levels of thioridazine by decreasing metabolism. Contraindicated. amiodarone will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.amisulprideContraindicated (2)amisulpride and thioridazine both increase QTc interval. Contraindicated. amisulpride, thioridazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.amitriptylineMonitor Closely (1)thioridazine and amitriptyline both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)thioridazine and amitriptyline both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)amitriptyline, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. amitriptyline, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.amobarbitalMonitor Closely (1)amobarbital and thioridazine both increase sedation. Use Caution/Monitor.Minor (1)thioridazine decreases levels of amobarbital by unspecified interaction mechanism. Minor/Significance Unknown.amoxapineMonitor Closely (2)thioridazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. thioridazine and amoxapine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)thioridazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)amoxapine, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. amoxapine, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.anagrelideContraindicated (1)anagrelide and thioridazine both increase QTc interval. Contraindicated.anticholinergic/sedative combosMonitor Closely (3)anticholinergic/sedative combos decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. anticholinergic/sedative combos decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. thioridazine increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.apomorphineContraindicated (1)apomorphine and thioridazine both increase QTc interval. Contraindicated.Serious - Use Alternative (1)thioridazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.arformoterolContraindicated (1)arformoterol and thioridazine both increase QTc interval. Contraindicated.Monitor Closely (1)thioridazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazoleContraindicated (1)aripiprazole and thioridazine both increase QTc interval. Contraindicated.Monitor Closely (2)aripiprazole and thioridazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. aripiprazole and thioridazine both increase sedation. Use Caution/Monitor.Minor (1)thioridazine will increase the level or effect of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.armodafinilMonitor Closely (1)thioridazine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.arsenic trioxideSerious - Use Alternative (1)thioridazine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.artemetherContraindicated (1)artemether and thioridazine both increase QTc interval. Contraindicated.artemether/lumefantrineSerious - Use Alternative (2)artemether/lumefantrine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. thioridazine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.asenapineContraindicated (1)asenapine and thioridazine both increase QTc interval. Contraindicated.Monitor Closely (1)asenapine and thioridazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)asenapine will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.asenapine transdermalContraindicated (1)asenapine transdermal and thioridazine both increase QTc interval. Contraindicated.Monitor Closely (1)asenapine transdermal and thioridazine both increase sedation. Use Caution/Monitor.atomoxetineContraindicated (1)atomoxetine and thioridazine both increase QTc interval. Contraindicated.Monitor Closely (1)thioridazine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atracuriumMonitor Closely (3)atracurium decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. atracurium decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. thioridazine increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropineMonitor Closely (3)atropine decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. atropine decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. thioridazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)thioridazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMMonitor Closely (3)thioridazine increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. atropine IV/IM decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. atropine IV/IM decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.Minor (1)thioridazine increases toxicity of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.avapritinibMonitor Closely (1)avapritinib and thioridazine both increase sedation. Use Caution/Monitor.azelastineMonitor Closely (1)azelastine and thioridazine both increase sedation. Use Caution/Monitor.azithromycinMonitor Closely (1)thioridazine and azithromycin both increase QTc interval. Use Caution/Monitor.baclofenMonitor Closely (1)baclofen and thioridazine both increase sedation. Use Caution/Monitor.bedaquilineMonitor Closely (1)thioridazine and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closelybelladonna alkaloidsMonitor Closely (3)belladonna alkaloids decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. belladonna alkaloids decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. thioridazine increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.belladonna and opiumMonitor Closely (4)belladonna and opium decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. belladonna and opium decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. thioridazine increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. belladonna